PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis

Ray Y. Chen, Lori E. Dodd, Myungsun Lee, Praveen Paripati, Dima A. Hammoud, James M. Mountz, Doosoo Jeon, Nadeem Zia, Homeira Zahiri, M. Teresa Coleman, Matthew W. Carroll, Jong Doo Lee, Yeon Joo Jeong, Peter Herscovitch, Saher Lahouar, Michael Tartakovsky, Alexander Rosenthal, Sandeep Somaiyya, Soyoung Lee, Lisa C. GoldfederYing Cai, Laura E. Via, Seung Kyu Park, Sang Nae Cho, Clifton E. Barry

Research output: Contribution to journalArticlepeer-review

105 Citations (Scopus)


Definitive clinical trials of new chemotherapies for treating tuberculosis (TB) require following subjects until at least 6 months after treatment discontinuation to assess for durable cure, making these trials expensive and lengthy. Surrogate endpoints relating to treatment failure and relapse are currently limited to sputum microbiology, which has limited sensitivity and specificity. We prospectively assessed radiographic changes using 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) at 2 and 6 months (CT only) in a cohort of subjects with multidrug-resistant TB, who were treated with second-line TB therapy for 2 years and then followed for an additional 6 months. CT scans were read semiquantitatively by radiologists and were computationally evaluated using custom software to provide volumetric assessment of TB-associated abnormalities. CT scans at 6 months (but not 2 months) assessed by radiologist readers were predictive of outcomes, and changes in computed abnormal volumes were predictive of drug response at both time points. Quantitative changes in FDG uptake 2 months after starting treatment were associated with long-term outcomes. In this cohort, some radiologic markers were more sensitive than conventional sputum microbiology in distinguishing successful from unsuccessful treatment. These results support the potential of imaging scans as possible surrogate endpoints in clinical trials of new TB drug regimens. Larger cohorts confirming these results are needed.

Original languageEnglish
Article number265ra166
JournalScience Translational Medicine
Issue number265
Publication statusPublished - 2014 Dec 3

Bibliographical note

Publisher Copyright:
© 2014, American Association for the Advancement of Science. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this